Review articleA review on Alzheimer's disease pathophysiology and its management: an update
Introduction
Alzheimer's disease (AD) is one of the most common neurodegenerative disease and accounts for more than 80% of dementia cases worldwide in elderly people. It leads to the progressive loss of mental, behavioral, functional decline and ability to learn [1].
Approximately 200,000 people younger than 65 years with AD comprise the younger onset AD population; 5 million are age 65 years or older. It is expected that by 2050, one new case of AD is expected to develop every 33 seconds, or nearly a million new cases per year, and the total estimated prevalence is expected to be 13.8 million [2].
Since the time of Dr. Alois Alzheimer, neuropathologists have identified amyloid plaques and NFTs in the autopsied brains of people with AD, suggesting that these pathologies cause the disease [3]. Amyloid plaques are extracellular deposits of Aβ in the brain parenchyma and in the cerebral blood vessels where it is known as congophilic angiopathy also known as cerebral amyloid angiopathy (CAA). NFTs composed largely of paired helical filaments with hyperphosphorylated tau proteins, neuronal and synaptic loss [1].
Currently and/or “only” approved treatments by US Food and Drug Administration (FDA), includes five drugs that are used to treat the cognitive manifestations of AD AChEIs–rivastigmine (Exelon), galantamine (Razadyne, Reminyl), tacrine (Cognex), and donepezil (Aricept) and NMDA receptor antagonist–memantine (Namenda) that target symptoms at its best [4]. Each drug acts in a different way to delay the breakdown of Ach (a chemical in the brain important for memory). AD is associated with inadequate levels of this important neurotransmitter. Tacrine (Cognex) is rarely prescribed due to its serious side effects (liver damage). In general, Reminyl, Exelon and Aricept are most effective when treatment is begun in the early stages. Memantine (Namenda) is the only drug shown to be effective for the later stages of the disease. They have all been shown to modestly slow the progression of cognitive symptoms and reduce problematic behaviors in some people, but at least half of the people who take these drugs do not respond to them. These present treatment strategies only delay the progression of symptoms associated with AD [5]. Much effort is being directed towards the discovery of disease-modifying therapies which can block the progression of the disease (i.e. clinical symptoms) and drugs targeting various molecular pathways. For development of disease modifying therapies complete knowledge about the various metabolic pathways is essential which includes production of Aβ from APP, in vivo clearance and pathophysiological events that leads to fibril formation and deposition into plaques [6]. The present article reviews the advance achieved recently in the field of pathogenesis of AD and also revealing possible new drug candidate targets. The most likely expected treatment strategies includes γ- and β-secretase inhibitors, Aβ vaccination, Cu–Zn chelators, cholesterol lowering drugs, statins and non-steroidal anti-inflammatory drugs (NSAIDs) [3].
In this review, we discuss the supporting mechanisms of AD pathogenesis and progression. We also summarize the existing therapeutic strategies till date in correlation with the pathophysiological mechanisms for AD.
Section snippets
Pathophysiology of AD
With pathophysiology of AD, debate goes back to the Alzheimer's time 1907 when he observed the neuropathological features of the disease i.e. amyloidal plaques and hyperphosphorylated NFTs. Several hypotheses have been put forward on the basis of the various causative factors in order to explain this multifactorial disorder [7] such as the cholinergic hypothesis, Aβ hypothesis, tau hypothesis and inflammation hypothesis [6]. Recently it has been shown that the most commonly used Aβ hypotheses,
Management of AD
The currently available treatment strategies include AChEIs and NMDA receptor antagonists [23]. In order to modify the disease process novel strategies have been developed. In this regard major developing is targeted to the Aβ and tau based therapeutics, which is a major key to unlock this disease in the near future [1], [6]. In this paper we highlight the currently approved treatment along with some disease modifying therapeutic drug targets.
Targeting Aβ protein (anti-amyloid approach)
The anti-amyloid therapeutics targets several aspects of APP metabolism [24].
Conclusion
In this paper we learn more detail about the pathophysiology and disease progression of AD and an insight into the potential therapeutic targets. Despite of the bulk of knowledge regarding this complex disease, only a fistful options are available for its management. Currently available drugs (AChEIs and memantine) for the treatment unfortunately target symptoms only and not the cause of the disease. So, the hope is now raised for the novel therapies that act at the root of the disease process
Conflict of interest
None declared.
Funding
Financial support from Rajiv Gandhi National Fellowship (RGNF) is gratefully acknowledged.
References (111)
- et al.
Therapeutics of Alzheimer's disease: past, present and future
Neuropharmacology
(2014) Alzheimer's disease: critical notes on the history of a medical concept
Arch Med Res
(2012)- et al.
Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies
Prog Neurobiol
(2002) - et al.
Novel insights for the treatment of Alzheimer's disease
Prog Neuropsychopharmacol Biol Psychiatry
(2011) - et al.
Immunotherapy against amyloid pathology in Alzheimer's disease
J Neurol Sci
(2013) - et al.
Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease
Prog Neurobiol
(2012) - et al.
Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain
Brain Res
(2001) - et al.
The role of inflammation in Alzheimer's disease
Int J Biochem Cell Biol
(2005) - et al.
Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology
Mech Ageing Dev
(2006) - et al.
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders
Brain Res Rev
(2000)
Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice
J Biol Chem
Passive immunization with anti-tau antibodies in two transgenic models reduction of tau pathology and delay of disease progression
J Biol Chem
Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation
Biochem Biophys Res Commun
The serotonergic system in ageing and Alzheimer's disease
Prog Neurobiol
A role for the 5-HT 1A, 5-HT 4 and 5-HT 6 receptors in learning and memory
Trends Pharmacol Sci
Caffeine and adenosine A 2a receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in mice
Exp Neurol
Dendritic pathology in Alzheimer's disease
J Neurol Sci
The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?
Adv Drug Deliv Rev
Alternative mitochondrial electron transfer as a novel strategy for neuroprotection
J Biol Chem
Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data
Alzheimers Dement
Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type
Neuroscience
Cholesterol and statins in Alzheimer's disease: current controversies
Exp Neurol
Alzheimer's disease facts and figures
Alzheimers Dement
Treatment options in Alzheimer's disease: maximizing benefit, managing expectations
Dement Geriatr Cogn Disord
Neuropathology and therapeutic management of Alzheimer's disease – an update
Drugs Future
The amyloid hypothesis for Alzheimer's disease: a critical reappraisal
J Neurochem
Do astrocytes collaborate with neurons in spreading the “infectious” Aβ and tau drivers of Alzheimer's disease?
Neuroscientist
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs
Br J Clin Pharmacol
Immunotherapy for targeting tau pathology in Alzheimers disease and tauopathies
Curr Alzheimer Res
A theory of cortical neuron–astrocyte interaction
Neuroscientist
Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation
Biol Res
Cholesterol is necessary both for the toxic effect of Aβ peptides on vascular smooth muscle cells and for Aβ binding to vascular smooth muscle cell membranes
J Neurochem
Alzheimer's disease: an update of the roles of receptors, astrocytes and primary cilia
Int J Mol Med
Alzheimer's pathogenesis: is there neuron-to-neuron propagation?
Acta Neuropathol
Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis
Science
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss
Proc Natl Acad Sci U S A
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Nature
Clearing amyloid through the blood–brain barrier
J Neurochem
Clearance of amyloid-β by circulating lipoprotein receptors
Nat Med
RAGE and Alzheimer's disease: a progression factor for amyloid-β-induced cellular perturbation?
J Alzheimers Dis
Developing β-secretase inhibitors for treatment of Alzheimer's disease
J Neurochem
β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice
FASEB J
Tramiprosate in mild-to-moderate Alzheimer's disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Al phase Study)
Arch Med Sci
Scyllo-inositol (ELND005) ameliorates amyloid pathology in an aggressive mouse model of Alzheimer's disease
Alzheimers Dement
Colostral proline-rich polypeptides – immunoregulatory properties and prospects of therapeutic use in Alzheimers disease
Curr Alzheimer Res
Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade
Proc Natl Acad Sci U S A
Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation
Nat Med
Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial
J Alzheimers Dis
Clinical observations with AN-1792 using TAPIR analyses
Neurodegener Dis
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nat Med
Cited by (1152)
A vivid outline demonstrating the benefits of exosome-mediated drug delivery in CNS-associated disease environments
2024, Archives of Biochemistry and Biophysics